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Introduction: Many patients with chronic obstructive pulmonary disease or asthma experience diﬃculties in
coordinating inhalation with pressurized metered-dose inhaler (pMDI) actuation. The use of a spacer device can
improve drug delivery in these patients. The aim of this study was to establish the relative bioavailability of
single doses of Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/actuation (2 actuations) used with and
without a spacer device. In addition, an in vitro study was conducted to characterize performance of the inhaler
when used in conjunction with a spacer device.
Methods: A Phase I, randomized, open-label, single-dose, single-center, crossover study in 50 healthy volunteers
(NCT02934607) assessed the relative bioavailability of single-dose Symbicort® pMDI 160/4.5 μg/actuation (2
actuations) with and without a spacer (AeroChamber Plus® Flow-Vu®). Inhaled doses were administered without
or with activated charcoal (taken orally) to estimate total systemic exposure and exposure through the lung,
respectively. The in vitro study characterized the eﬀect of the spacer with respect to delivered dose, ﬁne particle
dose, and dose during simulated breathing of budesonide and formoterol.
Results: In terms of total systemic exposure, use of the spacer increased the relative bioavailability determined
by AUC(0-last) and Cmax by 68% (spacer:no spacer treatment ratio, 167.9%; 90% CI, 144.1 to 195.6) and 99%
(ratio, 198.7%; 90% CI, 164.4 to 240.2) for budesonide, and 77% (ratio, 176.6%; 90% CI, 145.1 to 215.0) and
124% (ratio, 223.6%; 90% CI, 189.9 to 263.3) for formoterol, respectively, compared with pMDI alone.
Similarly, the lung exposure of budesonide and formoterol increased (AUC(0-last) and Cmax by 146% [ratio,
246.0%; 90% CI, 200.7 to 301.6] and 127% [ratio, 226.5%; 90% CI, 186.4 to 275.4] for budesonide, and 173%
[ratio, 272.8%; 90% CI, 202.5 to 367.4] and 136% [ratio, 236.2%; 90% CI, 192.6 to 289.6] for formoterol,
respectively) when the pMDI was administered through the spacer.
When assessed by AUC(0-last) quartile without spacer, subjects in the lowest exposure quartile (indicating poor
inhalation technique) with Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) had markedly increased total
systemic and lung exposure when the same dose was administered with the spacer. In contrast, for subjects in the
highest exposure quartile with pMDI alone, total systemic and lung exposure of formoterol and budesonide was
similar with and without the spacer.
In the in vitro study, the ﬁne particle dose (< 5 μm) of both budesonide and formoterol from the spacer at
delay time (i.e. pause period after actuation)= 0 s (instantaneous) after actuation was similar to the ﬁne particle
dose when not using the spacer. The delivered doses of budesonide and formoterol from the spacer were both
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T
lower compared with the doses administered without the spacer. There was also a decrease in delivered dose
with increasing delay time.
Conclusions: The clinical study demonstrated that in subjects with poor inhalation technique the use of the
AeroChamber Plus® Flow-Vu® spacer increased the bioavailability of Symbicort® pMDI to a level observed in
subjects with good inhalation technique without a spacer. The ﬁndings from the in vitro study support the ﬁne
particle dose characteristics of Symbicort® pMDI with the AeroChamber Plus® Flow-Vu® spacer.
1. Introduction
Observational studies have shown there is a signiﬁcant relationship
between the quality of inhaler use and control of symptoms in patients
with chronic obstructive pulmonary disease (COPD) and asthma [1].
Indeed, previous studies have demonstrated that around 75% of pa-
tients with COPD had poor inhalation technique when using a pres-
surized metered-dose inhaler (pMDI) [2]. Similar results have been
observed in patients with asthma [3,4]. Speciﬁcally, studies evaluating
inhalation technique have identiﬁed that the most common critical
handling errors with pMDIs are related to coordination of inhalation
with inhaler actuation [5]. Poor inhalation technique leads to decreased
medication delivery to the lungs and, in turn, poor disease control [6].
In patients who experience diﬃculties in coordinating inhalation with
pMDI actuation, the use of a spacer device (also known as a valved
holding chamber device) can improve the eﬃciency of drug delivery
[2,7,8].
Symbicort®, a combination of the inhaled corticosteroid (ICS) bu-
desonide and the rapid and long-acting β2-adrenoceptor agonist for-
moterol, is commercially available as a dry powder inhaler (DPI)
(Symbicort® Turbuhaler®) and pMDI (Symbicort® pMDI). It has been
shown to be eﬀective in reducing exacerbations and improving symp-
toms in patients with moderate-to-severe COPD or asthma, either via a
DPI or a pMDI [9–14]. Budesonide provides a high local anti-in-
ﬂammatory eﬀect within the lungs and airways, while formoterol re-
sults in a rapid and long-acting relaxation of bronchial smooth muscle
in patients with reversible airway construction [15]. Budesonide un-
dergoes rapid, extensive and reversible esteriﬁcation in the lungs,
readily dissolves in bronchial secretions, and is rapidly and extensively
absorbed with maximum plasma concentration reached within 30min
[16]. Formoterol is rapidly absorbed and a maximum plasma con-
centration is reached within 10min [16].
The present study was designed to establish the relative bioavail-
ability of Symbicort® (budesonide/formoterol) pMDI with and without
a spacer device (AeroChamber Plus® Flow-Vu®; Trudell Medical
International, London, Ontario, Canada) in healthy volunteers. In ad-
dition to the clinical study, an in vitro study was conducted to char-
acterize the AeroChamber Plus® Flow-Vu® spacer when applied together
with Symbicort® pMDI, with regard to how the use of the spacer aﬀects
the ﬁne particle dose (< 5 μm) delivered by Symbicort® pMDI ac-
cording to standard methods [17].
2. Materials and methods
2.1. Clinical study
This was a randomized, open-label, single-center, crossover study in
healthy volunteers (ClinicalTrials.gov identiﬁer: NCT02934607). The
primary objective was to establish the relative bioavailability of
Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/actuation (2
actuations) with and without a spacer (AeroChamber Plus® Flow-Vu®),
when administered without or with activated oral charcoal to estimate
total systemic exposure and exposure through the lung, respectively.
The secondary objectives were to characterize the pharmacokinetic
(PK) proﬁles of budesonide and formoterol delivered via a pMDI with
and without a AeroChamber Plus® Flow-Vu® spacer without or with
activated charcoal, and to assess the safety of single doses of Symbicort®
160/4.5 μg/actuation (2 actuations) pMDI in healthy subjects.
Subjects were screened for a maximum of 28 days before rando-
mization, which was followed by four treatment periods during which
the subjects were resident in the Phase I Unit from the afternoon before
dosing with Symbicort® pMDI until at least 24 h after dosing. At each
treatment visit, subjects received (under fasting conditions) two ac-
tuations of Symbicort® pMDI (160/4.5 μg/actuation) delivered with or
without the AeroChamber Plus® Flow-Vu® spacer without or with acti-
vated charcoal, resulting in four treatment groups: A: pMDI alone, no
charcoal; B: pMDI + AeroChamber Plus® Flow-Vu® spacer, no charcoal;
C: pMDI with charcoal; D: pMDI + AeroChamber Plus® Flow-Vu® spacer
with charcoal (Table 1). Device and inhalation training using a placebo
pMDI (identical to Symbicort® pMDI) with or without the AeroChamber
Plus® Flow-Vu® spacer was conducted on admission to each treatment
period and prior to dosing on Day 1 of each treatment period.
Blood samples were taken pre-dose and at 5, 20, and 40min and at
1, 2, 4, 8, 10, 12, 18, and 24 h after Symbicort® pMDI dosing for de-
termination of plasma concentrations of budesonide and formoterol. A
ﬁnal visit occurred 5 to 7 days following the last drug administration.
Between each treatment period, there was a minimum washout period
of 3 days.
The charcoal block technique, as described by Thorsson et al. [18],
was used to assess lung exposure. Activated charcoal was prepared as a
charcoal-water suspension (approximately 10 g charcoal in 80mL of
water) and given orally at repeated intervals: immediately before in-
halation, immediately after dosing (following the mouth rinse), 1 h
after administration, and 2 h after inhalation. Subjects rinsed their
mouths with water after each charcoal administration, but this water
was not swallowed. Subjects were trained by study personnel to per-
form inhalation techniques correctly on admission to each treatment
Table 1
Treatment groups.
Treatment group Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/actuation (2
actuations)
AeroChamber Plus® Flow-Vu® spacer Charcoal block
A ✓ Total systemic exposure
B ✓ ✓
C ✓ ✓ Lung exposure
D ✓ ✓ ✓
Comparison B versus A (reference) evaluated the eﬀect of the spacer on total systemic exposure; comparison D versus C (reference) evaluated the eﬀect of the spacer
on lung exposure.
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period and prior to dosing, in order to achieve reproducibility of in-
halation. Subjects rinsed their mouths twice with 25mL of water after
administration of Symbicort® pMDI.
The safety endpoints for this study were the occurrence of adverse
events (AEs) and laboratory/vital signs abnormalities, summarized by
treatment and overall. AEs were coded using the MedDRA dictionary
version 19.1. A treatment-emergent AE was deﬁned as an AE with onset
after ﬁrst dose, including AEs occurring during the washout between
successive treatment periods.
The study was performed in accordance with ethical principles that
have their origin in the Declaration of Helsinki and was consistent with
the International Council for Harmonisation Good Clinical Practice
guidelines. The clinical study protocol was approved by an Independent
Ethics Committee (South Central – Berkshire B Research Ethics
Committee, Bristol HRA Centre, Level 3, Block B, Whitefriars, Lewins
Mead, Bristol BS1 2NT, UK; Reference 16/SC/0461) and the Medicines
and Healthcare Products Regulatory Agency.
2.1.1. Subjects
Healthy male and female non-smokers aged≥18 years with a body
mass index of 18–30 kg/m2, and weight ≥50–≤100 kg were eligible
for participation. Subjects were required to have a forced expiratory
volume in 1 s (FEV1) of≥80% of the predicted value, and FEV1/forced
vital capacity ratio ≥70%. No concomitant medication or therapy was
permitted (with the exception of oral paracetamol and hormone re-
placement therapy/systemic contraceptives in females). Females were
required to have a negative pregnancy test at screening and on ﬁrst
admission, and to not be lactating.
2.1.2. Pharmacokinetic measurements
The primary PK parameters for relative bioavailability criteria were
maximum observed plasma concentration (Cmax) and area under the
plasma concentration-time curve from time zero to time of last quan-
tiﬁable concentration (AUC0-last). The secondary PK parameters in-
cluded area under the plasma concentration-time curve from zero to
inﬁnity (AUC), time to reach maximum observed plasma concentration
(tmax), half-life associated with terminal slope (λz) of semi-logarithmic
concentration-time curve (t½λ), apparent volume of distribution during
the terminal phase (extravascular administration) (Vz/F), and apparent
total body clearance of drug from plasma after extravascular adminis-
tration (CL/F).
2.1.3. Statistical analysis
All subjects who received at least one dose of Symbicort® pMDI, and
for whom any safety post-dose data were available were included in the
safety analysis.
The PK analysis set consisted of all subjects in the safety analysis set
for whom at least one of the primary PK parameters for a given analyte
could be calculated, and for whom no important protocol deviations
thought to impact on the analysis of PK data occurred.
The purpose of this study was to estimate any diﬀerence in the PK of
Table 2
Participant baseline demographics.
Parameter Subjects (N=50)
Mean age, years (SD) 42.2 (16.3)
Males, n (%) 28 (56.0)
Race, n (%)
White 36 (72.0)
Black or African American 5 (10.0)
Asian 4 (8.0)
Other 5 (10.0)
Mean highest FEV1% predicted (SD) 104.8 (13.8)
Mean FEV1, L (SD) 3.7 (1.0)
Mean BMI, kg/m2 (SD) 24.4 (2.9)
BMI, body mass index; SD, standard deviation.
Fig. 1. Plasma budesonide concentration-
time proﬁles following administration of
Symbicort® (budesonide/formoterol) pMDI
160/4.5 μg/actuation (2 actuations) with
and without a spacer, a) total systemic ex-
posure (no charcoal block) and b) lung ex-
posure (with charcoal block) (pharmacoki-
netic analysis set, linear scale). Bars
represent geometric standard deviation.
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budesonide and formoterol with adequate precision; all analyses were
considered to be descriptive in nature. Assuming an intra-subject
coeﬃcient of variation of 33% (based on the variability of AUC0–12h for
budesonide and AUC0–12h and Cmax for formoterol observed in a simi-
larly designed crossover study in healthy adults) [19] and an expected
diﬀerence of 0, forty four (44) evaluable subjects provided at least 80%
power to show that the 90% conﬁdence interval (CI) for the treatment
eﬀects fell entirely within the range 0.8–1.25, i.e., ruled out a 20%
change (on a log scale) in exposure to budesonide and formoterol. It
was considered appropriate to base the sample size on AUC0–12h for
budesonide rather than Cmax (which has higher variability) because the
eﬀects of ICS are more likely related to total systemic exposure (i.e.,
AUC) rather than to acute exposure (i.e., Cmax). Additional subjects
were randomized to ensure that at least 44 evaluable subjects com-
pleted the study.
A two-sided 90% CI approach based on a repeated measures ana-
lysis of variance (ANOVA) model was used to assess the primary PK
parameters, including period and treatment as ﬁxed eﬀects, and parti-
cipant as a random eﬀect. All PK parameters were log-transformed prior
to analysis. The estimated treatment diﬀerences and the 90% CIs on the
Fig. 2. Plasma formoterol concentration-
time proﬁles following administration of
Symbicort® (budesonide/formoterol) pMDI
160/4.5 μg/actuation (2 actuations) with
and without a spacer, a) total systemic ex-
posure (no charcoal block) and b) lung ex-
posure (with charcoal block) (pharmacoki-
netic analysis set, linear scale). Bars
represent geometric standard deviation.
Table 3
Secondary pharmacokinetic parameters.
Parameter, unit Symbicort® pMDI alone
(A) (N=49)
Symbicort® pMDI + AeroChamber Plus® Flow-
Vu® (B) (N=48)
Symbicort® pMDI alone
(C) (N=49)
Symbicort® pMDI + AeroChamber Plus® Flow-
Vu® (D) (N=48)
—— Total systemic exposure —— —— Lung exposure ——
Budesonide
AUC, h*pg/mLa 788.2 (70.4) 1308.0 (33.3) 608.4 (77.1) 1253.0 (47.0)
tmax, hb 0.3 (0.1, 1.0) 0.3 (0.1, 1.0) 0.3 (0.1, 0.7) 0.3 (0.1, 0.7)
t½λz, hc 3.4 (1.0) 3.7 (1.2) 2.9 (0.9) 3.3 (1.1)
Vz/F, Lc 2253.0 (1469.0) 1308.0 (390.9) 2546.0 (1676.0) 1284.0 (725.8)
CL/F, L/hc 503.6 (392.4) 258.2 (91.9) 660.3 (462.5) 290.7 (222.2)
Formoterol
AUC, h*pg/mLa 66.5 (29.7) 62.2 (29.9) 66.8 (NC) 52.4 (24.7)
tmax, hb 0.3 (0.1, 8.0) 0.1 (0.1, 0.7) 0.1 (0.1, 0.7) 0.1 (0.1, 0.7)
t½λ, hc 5.8 (1.5) 6.3 (1.5) 5.8 (1.7) 5.9 (1.7)
Vz/F, Lc 1096.0 (181.2) 1278.0 (276.3) 1601.0 (NA) 1357.0 (150.8)
CL/F, L/hc 140.1 (39.7) 150.3 (42.2) 134.7 (NC) 176.1 (39.5)
Data shown as ageometric mean (CV%); bmedian (min, max); carithmetic mean (SD). Comparison B versus A (reference) evaluated the eﬀect of the spacer on total
systemic exposure; comparison D versus C (reference) evaluated the eﬀect of the spacer on lung exposure. AUC, area under the plasma concentration-time curve from
time zero extrapolated to inﬁnity; CL/F, apparent total body clearance of drug from plasma after extravascular administration; CV, coeﬃcient of variation; pMDI,
pressurized metered-dose inhaler; NC, not calculable; t½λ, half-life associated with terminal slope (λz) of a semi logarithmic concentration time curve; tmax, time to
reach maximum observed plasma concentration; Vz/F, apparent volume of distribution during the terminal phase (extravascular administration).
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log scale were back-transformed to obtain the Gmean ratios for each pair
of treatments. The least square means (and 95% CIs), Gmean ratios, and
90% CIs were tabulated for each comparison and analyte (budesonide
and formoterol).
An additional ANOVA model including sequence, subject within
sequence, period, and treatment as ﬁxed eﬀects (with no random ef-
fects) was incorporated in the analysis.
The treatment ratio of each of the test formulations (i.e., with the
spacer) were compared with the reference formulations (i.e., without
the spacer) for both budesonide and formoterol. In order to determine
total systemic exposure, statistical analyses were conducted comparing
treatments without charcoal, whereas to determine lung exposure,
analyses were conducted comparing treatments with charcoal (see
Table 1).
An additional analysis was included post database lock, assessing
subjects split by AUC(0-last) quartile during no spacer treatment.
Spacer:No spacer ratios were calculated for AUC(0-last) and Cmax for each
quartile. Quartile 1 had the lowest AUC(0-last) values, indicative of poor
inhalation technique, and Quartile 4 had the highest AUC(0-last) values,
indicative of good inhalation technique.
2.2. In vitro study
The AeroChamber Plus® Flow-Vu® spacer was used after removing
from the package, without any pre-treatment, according to the manu-
facturer's instructions. Symbicort® (budesonide/formoterol) pMDI 160/
4.5 μg/actuation (2 actuations) was primed prior to use (according to
the patient instruction leaﬂet) and 10 waste actuations were pressed,
similar to the handling of the pMDIs used in the clinical study. The
Symbicort® pMDI was shaken before each of the two test actuations.
Delay times (i.e. pause periods after actuation) of 0 s (instantaneous),
2 s, and 5 s were applied after each actuation, before extraction of the
dose from the AeroChamber Plus® Flow-Vu® spacer. The delivered dose
from the spacer was collected on Respirgard® disposable ﬁlters (Vital
Signs, Totowa, New Jersey, USA) at a ﬂow rate of 30 L/min. For each
delay time, three doses were collected from each of three ﬁxed
Symbicort® pMDI/AeroChamber Plus® Flow-Vu® spacer combinations
(one single pMDI was always combined with the same spacer), resulting
in a total of nine doses collected for each delay time (one dose per ﬁlter
was collected). The dose was then recovered from the ﬁlter using an
internal standard technique. The simultaneous quantiﬁcation of bude-
sonide and formoterol was performed using high-performance liquid
chromatography (HPLC) with a C18-column (XTerra RP-18 3.5 μm,
50 × 4.6 mm) at 25 °C with acetonitrile/25 mM sodium phosphate
buﬀer pH 3.0 + 15 mM sodium octanesulfonic acid 30/70 (vol/vol) as
mobile phase and a ﬂow rate of 2 mL/min using a detection wavelength
of 214 nm and a runtime of 6 min. The aerosol particle size distribution
was assessed using a Next Generation Impactor. Three sample doses
from each of three ﬁxed Symbicort® pMDI/AeroChamber Plus® Flow-
Vu® spacer combinations were collected at a ﬂow rate of 30 L/min and
analyzed by HPLC assay using same conditions as above. Linear inter-
polation of the discrete values bordering the mass median aerosol
diameter in a log-probability plot was used for determining the median
mass aerodynamic diameter from impactor stage data. The breathing
proﬁle generator F-SIG 6300 (AB FIA, Södra Sandby, Sweden) was used
to generate the two diﬀerent adult breathing patterns used, according
to Canadian Standards Association Guidance Z264.1–02 [20]. One
breathing pattern (Adult 1) used the following parameters: tidal volume
770mL, frequency 12/min, inspiratory/expiratory (I/E) ratio 1:2 and
minute volume 9240mL. The second pattern (Adult 2) used tidal vo-
lume 500mL, frequency 13/min, I/E ratio 1:2 and minute volume
6200mL. The pMDI was actuated into the AeroChamber Plus® Flow-Vu®
spacer immediately before the start of the inhalation part of the
breathing cycle and the dose was collected ex-spacer using the
breathing proﬁle.
3. Results
3.1. Clinical study
3.1.1. Subjects
A total of 50 healthy subjects were randomized and received the
study medication; all of whom were included in the safety and PK
analysis sets. Subjects' demographics are presented in Table 2. Two
individuals discontinued after their ﬁrst treatment (one subject failed
the drugs of abuse test on admission to treatment period 2 and the other
subject withdrew consent after treatment period 1. The latter was not
due to safety reasons); the remaining 48 subjects completed the study.
3.1.2. Pharmacokinetics
Plasma concentration-time proﬁles for budesonide and formoterol
are depicted in Figs. 1 and 2, and the secondary plasma PK parameters
are summarized in Table 3. Absorption of both budesonide and for-
moterol was rapid following administration of Symbicort® pMDI with
and without the spacer and without or with charcoal (reﬂecting total
systemic and lung exposure, respectively) (Figs. 1 and 2).
Table 4
Budesonide and formoterol plasma pharmacokinetic parameters in healthy volunteers following single-dose Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/
actuation (2 actuations) with or without spacer (AeroChamber Plus® Flow-Vu®) for total systemic and lung exposure.
Parameter, unit
Geometric mean
(CV%)
Symbicort® pMDI
alone (A)
(N=49)
Symbicort®
pMDI + AeroChamber Plus®
Flow-Vu® (B) (N=48)
Pairwise
comparison B vs A
Ratio, % [90% CI]
Symbicort® pMDI
alone (C)
(N=49)
Symbicort®
pMDI + AeroChamber Plus®
Flow-Vu® (D) (N=48)
Pairwise comparison
D vs C Ratio, %
[90% CI]
——————— Total systemic exposure ——————— ——————— Lung exposure ———————
Budesonide
Cmax, pg/mL 254.8 (105.5) 524.9 (40.1) 198.7 [164.4,
240.2]
231.7 (95.9) 495.4 (51.3) 226.5 [186.4,
275.4]
AUC(0-last), h*pg/
mL
740.9 (84.8) 1284.0 (35.1) 167.9 [144.1,
195.6]
527.6 (103.7) 1212 (45.3) 246.0 [200.7,
301.6]
Formoterol
Cmax, pg/mL 4.2 (73.2) 9.3 (52.1) 223.6 [189.9,
263.3]
4.6 (56.7) 9.2 (58.7) 236.2 [192.6,
289.6]
AUC(0-last), h*pg/
mL
19.9 (115.6) 34.6 (60.6) 176.6 [145.1,
215.0]
13.6 (119.1) 32.4 (57.7) 272.8 [202.5,
367.4]
Comparison B versus A (reference) evaluated the eﬀect of the spacer on total systemic exposure; comparison D versus C (reference) evaluated the eﬀect of the spacer
on lung exposure.
AUC(0-last), area under the plasma concentration-time curve from time zero to the last quantiﬁable concentration after dosing; CI, conﬁdence interval; Cmax, observed
maximum plasma concentration; CV, coeﬃcient of variation; pMDI, pressurized metered-dose inhaler.
M. Gillen et al. Pulmonary Pharmacology & Therapeutics 52 (2018) 7–17
11
Fig. 3. Eﬀect of the AeroChamber Plus® Flow-Vu® spacer on plasma pharmacokinetic parameters as determined by ratios of Spacer:No spacer for AUC(0-last) and Cmax
of a) budesonide and b) formoterol according to exposure quartile (1st–4th)* (pharmacokinetic analysis set). No charcoal block corresponds to total systemic
exposure; charcoal block corresponds to lung exposure.
*Data were divided into quartiles based on AUC(0-last) during no spacer treatment.
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For budesonide, median tmax occurred at 20min post-dose both with
and without the spacer and without or with charcoal block. For for-
moterol, the median tmax occurred at 20min and 5min post-dose with
and without the spacer, respectively. When administered concomitantly
with activated charcoal, the formoterol median tmax occurred at 5min
(range: 4 to 40min) post-dose with or without the spacer (Table 3).
Between-subject variability (Table 4) of budesonide and formoterol
was high and more pronounced in treatments without the spacer. For
total systemic exposure, geometric intra-subject coeﬃcient of variation
(CV%) of AUC (Table 3), AUC(0-last), and Cmax ranged from 70% to
106% for Treatment A, and 33% to 40% for Treatment B for budeso-
nide, and 116% and 73% for Treatment A and 61% and 52% for
Treatment B for formoterol. Similarly for lung exposure, geometric CV
% of AUC, AUC(0-last), and Cmax ranged between 77% and 104% for
Treatment C and 45% to 51% for Treatment D for budesonide, and 57%
and 119% for Treatment C and 58% and 59% for Treatment D for
formoterol (Table 4).
Compared with pMDI alone, use of the spacer increased the total
systemic exposure of budesonide and formoterol. Thus, the relative
bioavailability, as determined by AUC(0-last) and Cmax was 68% and 99%
higher, respectively, for budesonide, and 77% and 124% higher, re-
spectively, for formoterol (Table 4). Similarly, the lung exposure of
budesonide and formoterol increased when the pMDI was administered
through the spacer: the relative bioavailability, as determined by
AUC(0-last) and Cmax, increased by 146% and 127%, respectively, for
budesonide, and by 173% and 136%, respectively, for formoterol
(Table 4).
An additional analysis was performed separating subjects into four
groups based on exposure (AUC0-last) quartiles with pMDI alone (Fig. 3).
Subjects in the lowest exposure quartile (indicative of poor inhalation
technique) had increased total systemic exposure of budesonide when
Symbicort® pMDI was administered with the spacer (Fig. 3a). In con-
trast, for subjects in the highest exposure quartile with pMDI alone
(indicative of good inhalation technique), total systemic and lung ex-
posure of budesonide was similar with and without the spacer (Fig. 3a).
Similar trends were observed for formoterol (Fig. 3b).
3.1.3. Safety
In this cohort of healthy individuals, there were no deaths, serious
AEs, or AEs leading to discontinuation of treatment reported. Thirty
subjects (60%) reported≥1 AE during this study. All AEs were mild to
moderate in intensity; the most common being headache and dizziness.
No clinically relevant ﬁndings were observed in laboratory data or vital
signs.
3.2. In vitro study
The in vitro study demonstrated that the AeroChamber Plus® Flow-
Fig. 4. Results from the in vitro study showing a) ﬁne particle dose< 5 μm, with the AeroChamber Plus® Flow-Vu® spacer at diﬀerent delay times, in percentage of
label claim; b) dose with spacer at diﬀerent delay times, in percentage of label claim; and c) dose with spacer (breathing patterns), in percentage of label claim. All
data presented as mean ± SD.
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Vu® spacer performed as expected. If the dose was withdrawn (i.e.,
inhaled) from the spacer according to its instruction for use, without
any delay time, the ﬁne particle dose (< 5 μm) was very similar to the
ﬁne particle dose without spacer for both active substances. There was a
decrease in ﬁne particle dose with increasing delay time (Fig. 4a;
Table 5). The impactor sized distributions for Symbicort® pMDI with
and without the spacer for both active substances were very similar
taking into consideration the general decay over time (Fig. 5a + 5b). In
addition, the cumulative distribution data for Symbicort® pMDI with
and without the spacer for both active substances showed similar be-
havior (Fig. 6a + 6b). The delivered doses from the spacer decreased
for both budesonide and formoterol compared with the doses ad-
ministered with Symbicort® pMDI alone. There was also a decrease in
delivered dose with increasing delay time (Fig. 4b; Table 5).
When the spacer was used with simulated breathing patterns de-
signed to represent those of adults, the dose collected was similar for
the two patterns used when the pMDI was actuated immediately before
the inhalation part of the breathing cycle and similar to doses with-
drawn using constant ﬂow (Fig. 4c; Table 5). When the pMDI was ac-
tuated immediately before the exhalation part of the breathing cycle,
slightly lower doses were found, similar to the doses withdrawn with
constant ﬂow after a 2- to 5-second delay.
4. Discussion
In this clinical study, the relative total systemic and lung bioavail-
ability of Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/ac-
tuation (2 actuations) was increased when administered through the
AeroChamber Plus® Flow-Vu® spacer, compared with Symbicort® pMDI
alone. Indeed, administration of Symbicort® pMDI with the spacer in-
creased the total systemic exposure (AUC(0-last) and Cmax) of both bu-
desonide (68% and 99%, respectively) and formoterol (77% and 124%,
respectively). For evaluation of delivery of the components to the lung,
the charcoal block method was used to inhibit gastrointestinal
absorption of budesonide and formoterol. In this study, the percentage
increase in lung exposure with Symbicort® pMDI with spacer versus
Symbicort® pMDI alone was greater than the increase in total systemic
exposure; this is expected since the with-charcoal comparison reﬂects
the change in lung delivery with use of the spacer device. In the
without-charcoal comparison (i.e., total systemic exposure), the dif-
ference between exposure with Symbicort® pMDI and spacer versus
Symbicort® pMDI alone is aﬀected by the reduction in oral deposition/
absorption with the spacer device, as well as the improvement in lung
deposition due to improved coordination of inhalation. An increase in
exposure due to improved lung delivery is therefore oﬀset, to some
degree, by a reduction in gastrointestinal absorption. In previous stu-
dies with Symbicort® pMDI, budesonide and formoterol systemic ex-
posure (AUC(0-last) and Cmax) was approximately double that observed
in this study, but was similar to that seen following administration of
Symbicort® pMDI with the AeroChamber Plus® Flow-Vu® spacer
[19,21]. This suggests that, in the present study, a proportion of sub-
jects had poor inhalation technique, for whom the use of the spacer
overcame problems with inhalation coordination, as shown by the 3–4-
fold increase in exposure to budesonide and formoterol. However, for
those subjects who had high exposure with Symbicort® pMDI alone (i.e.,
indicative of good inhalation technique), exposure was relatively un-
changed by the spacer. Similar results were observed in patients treated
with beclometasone dipropionate/formoterol (100/6 μg) pMDI plus
AeroChamber Plus™ [22]. In that study, patients with poor inhalation
technique experienced an increase in peak plasma concentrations with
AeroChamber Plus™ [22]. Furthermore, in the present study, exposure
with the spacer in subjects who had a high ratio with:without spacer
(i.e., those in exposure quartiles 1 and 2) did not exceed that in subjects
in the highest exposure quartile regardless of spacer use. Such data
demonstrate that the increase in relative total systemic and lung bioa-
vailability caused by the spacer does not result in higher exposure than
in a subject who inhales properly.
The use of the AeroChamber Plus® Flow-Vu® spacer in the present
study did not increase the total systemic exposure to budesonide and
formoterol above what has been observed with Symbicort® pMDI in
previous studies [19,21]. Furthermore, exposure did not exceed values
observed with Symbicort® Turbuhaler®, a device which does not require
inhalation coordination like a pMDI, and has a similar well-established
safety proﬁle.
The safety results from this study in healthy volunteers were con-
sistent with the well-established safety proﬁle of Symbicort® in subjects
with COPD or asthma [10–14]. Plasma exposure to both drugs in-
creased when using the AeroChamber Plus® Flow-Vu® spacer; however,
total systemic exposure did not exceed the levels typically seen in
previous Symbicort® pMDI studies [19,21]. Furthermore, exposure was
relatively unchanged in subjects with good inhalation technique, so
there should be no increased risk to patients with COPD or asthma
when using the spacer in combination with the pMDI. Single doses of
Symbicort® (budesonide/formoterol) pMDI 160/4.5 μg/actuation (2
actuations) were well tolerated when administered with or without the
spacer, and without or with activated charcoal.
The in vitro study results conﬁrm that the AeroChamber Plus® Flow-
Vu® spacer performs as expected when used with Symbicort® pMDI. The
reduction in delivered dose observed when Symbicort® pMDI was ad-
ministered with the spacer can be attributed to the retention of mainly
coarse particles in the device due to particle impaction in the valve and
chamber, and sedimentation in the chamber. The decrease in ﬁne
particle dose with increased residence time for the aerosol in the
chamber could be attributed to impaction and retention due to some
remaining electrostatic charge. The increase in ﬁne particle fraction and
decrease in ﬁne particle dose with delay has been noted in an early
publication describing performance of the AeroChamber [23].
Expected dose delivery was obtained when the AeroChamber Plus®
Flow-Vu® spacer was used with simulated breathing patterns designed
to represent those of adults, indicating well-constructed inhalation and
Table 5
Results from the in vitro study showing ﬁne particle dose<5 μm in percentage
of label claim, ﬁne particle fraction in percentage of delivered dose to impactor,
median mass aerodynamic diameter and dose in percentage of label claim, all
with the AeroChamber Plus® Flow-Vu® spacer at diﬀerent delay times (N=9
doses for each delay time), and dose with spacer (breathing patterns) in per-
centage of label claim.
Parameter, unit Formoterol Budesonide
Fine particle dose < 5 μm, mean % (SD)
Ref without spacer 50.0 (3.3) 44.9 (1.7)
0 s delay 53.3 (2.6) 44.7 (3.5)
2 s delay 42.5 (2.2) 35.2 (2.5)
5 s delay 33.8 (2.3) 28.3 (2.9)
Fine particle fraction, mean % (SD)
Ref without spacer 60.9 (0.9) 53.2 (1.7)
0 s delay 81.3 (1.2) 73.6 (1.2)
2 s delay 79.7 (2.0) 72.3 (2.0)
5 s delay 79.9 (1.1) 73.1 (0.9)
Median mass aerodynamic diameter, μm
Ref without spacer 3.25 3.57
0 s delay 3.13 3.40
2 s delay 3.30 3.57
5 s delay 3.31 3.55
Delivered dose, mean % (SD)
Ref without spacer 86.7 (2.1) 89.5 (2.2)
0 s delay 58.7 (3.1) 56.0 (2.9)
2 s delay 44.2 (6.7) 41.3 (6.3)
5 s delay 40.3 (8.5) 37.4 (7.6)
Delivered dose with spacer (breathing patterns), mean % (SD)
Adult 1 67.3 (6.5) 61.7 (5.9)
Adult 2 64.3 (4.2) 58.8 (4.0)
SD, standard deviation. Nominal dose/label claim is 160/4.5 μg/actuation; a
patient dose consists of two actuations.
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Fig. 5. Individual impactor stage data at diﬀerent delay times, in percentage of label claim for a) budesonide and b) formoterol. All data are presented as
mean ± 90% conﬁdence intervals using the Student's t-distribution. MOC, micro-oriﬁce collector.
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exhalation valves of appropriate material not adding to signiﬁcant de-
position of the drug. Since the breathing proﬁles used were adult pro-
ﬁles with rather large inhalation volumes, a large part of the aerosol
was expected to be withdrawn from the spacer during the immediate
inhalation part of the ﬁrst breathing cycle, thus leading to a very short
aerosol residence time in the spacer with low deposition losses inside
the spacer.
The slightly lower doses found when the pMDI was actuated im-
mediately before the exhalation part of the breathing cycle (similar to
doses withdrawn with constant ﬂow after a 2- to 5-second delay) was
attributed to an increased residence time in the spacer before the
aerosol was withdrawn by the inhalation part of the next breathing
cycle. No obvious malfunction of the exhalation valve was identiﬁed,
since this would have resulted in lower doses.
This study has some limitations. Firstly, healthy subjects were used
throughout the study. This approach was taken to avoid the potential
for day-to-day variability in lung delivery in patient populations due to
their disease state that could aﬀect the PK data and enabled testing of
the eﬀect of the spacer without other interfering factors. However, PK
data with the Symbicort® pMDI in adults with COPD, and adults and
children with asthma show generally comparable PK proﬁles across the
populations [24]. The second limitation is the fact that this study only
used one spacer. The ﬁndings of this study may therefore not be uni-
versally applicable to other spacers that have diﬀerent geometry and
are constructed of diﬀerent materials, since these factors can inﬂuence
drug delivery. The AeroChamber Plus® Flow-Vu® spacer was chosen as it
is commonly used and widely available in the regions where Symbicort®
is marketed. The third limitation is the lack of spacer data in pediatrics.
Fig. 6. Cumulative distribution normalized to label claim for a) budesonide and b) formoterol. MOC, micro-oriﬁce collector.
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This study was conducted to support approval for a COPD indication for
Symbicort® pMDI in Europe, so pediatric data were not of concern. In
other regions, Symbicort® is approved for asthma patients as young as 6
years of age and in this age range an inspiratory volume to easily empty
a 150mL spacer would not be of concern.
5. Conclusions
The results observed in this clinical study clearly demonstrate the
beneﬁt of the AeroChamber Plus® Flow-Vu® spacer in terms of addres-
sing poor inhalation technique with Symbicort® (budesonide/for-
moterol) pMDI 160/4.5 μg/actuation (2 actuations). The use of the
spacer improved exposures in these subjects to a similar level as those
with a good inhalation technique without a spacer. The ﬁndings from
the in vitro study support the ﬁne particle dose characteristics of
Symbicort® pMDI with the AeroChamber Plus® Flow-Vu® spacer.
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